Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium While mutations in the ESR1 gene are exceedingly rare in cancer patients prior to treatment, the use of endocrine ...
6don MSN
Five mutational 'fingerprints' could help predict how visible tumors are to the immune system
Researchers from the HUN-REN Szeged Biological Research Centre and HCEMM have just published a new study suggesting that it's not simply the number of tumor mutations that matters for immunotherapy, ...
After decades of fixating on mutations in nuclear DNA as the prime suspects in cancer development, researchers are increasingly peering into the cell’s powerhouse for clues. Mutations in mitochondrial ...
Researchers in the U.K. have overthrown the orthodox view that childhood cancers have a low mutation burden, opening up new drug targets and opportunities for repurposing existing therapies. In ...
MINNEAPOLIS, Dec. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results